Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
68
HOCPY Quote, Financials, Valuation and Earnings
Last price:
$151.90
Seasonality move
:
-0.44%
Day range:
$149.68 - $150.29
52-week range:
$97.49 - $168.00
Dividend yield:
0%
P/E ratio:
36.75x
P/S ratio:
8.62x
P/B ratio:
7.49x
Volume:
12.9K
Avg. volume:
15.7K
1-year change:
18.72%
Market cap:
$51B
Revenue:
$5.7B
EPS (TTM):
$4.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
HOCPY
HOYA Corp.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
HOCPY
HOYA Corp.
|
$149.90 | -- | $51B | 36.75x | $0.80 | 0% | 8.62x |
|
HLOSF
Healios KK
|
$1.93 | -- | $222.8M | -- | $0.00 | 0% | 303.04x |
|
PPTDF
PeptiDream Inc.
|
$11.98 | -- | $1.5B | 13.79x | $0.00 | 0% | 12.90x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.48 | -- | $495.9M | -- | $0.00 | 0% | 2.56x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$15.76 | $17.93 | $49.8B | 200.00x | $0.32 | 4.2% | 1.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
HOCPY
HOYA Corp.
|
3.97% | 1.099 | 0.6% | 4.06x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
HOCPY
HOYA Corp.
|
$1.3B | $461M | 20.27% | 21.03% | 29% | $407M |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
HOYA Corp. vs. Competitors
-
Which has Higher Returns HOCPY or HLOSF?
Healios KK has a net margin of 23.44% compared to HOYA Corp.'s net margin of -9751.87%. HOYA Corp.'s return on equity of 21.03% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital HOCPYHOYA Corp.79.54% $1.10 $7.1B HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About HOCPY or HLOSF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Healios KK, analysts believe HOYA Corp. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings HOCPYHOYA Corp.0 0 0 HLOSFHealios KK0 0 0 -
Is HOCPY or HLOSF More Risky?
HOYA Corp. has a beta of 1.019, which suggesting that the stock is 1.938% more volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock HOCPY or HLOSF?
HOYA Corp. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 21.95% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPY or HLOSF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Healios KK quarterly revenues of $128.8K. HOYA Corp.'s net income of $372.7M is higher than Healios KK's net income of $3.8M. Notably, HOYA Corp.'s price-to-earnings ratio is 36.75x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.62x versus 303.04x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPYHOYA Corp.8.62x 36.75x $1.6B $372.7M HLOSFHealios KK303.04x -- $128.8K $3.8M
-
Which has Higher Returns HOCPY or PPTDF?
PeptiDream Inc. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -25.38%. HOYA Corp.'s return on equity of 21.03% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital HOCPYHOYA Corp.79.54% $1.10 $7.1B PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About HOCPY or PPTDF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than PeptiDream Inc., analysts believe HOYA Corp. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOCPYHOYA Corp.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is HOCPY or PPTDF More Risky?
HOYA Corp. has a beta of 1.019, which suggesting that the stock is 1.938% more volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock HOCPY or PPTDF?
HOYA Corp. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 21.95% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPY or PPTDF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. HOYA Corp.'s net income of $372.7M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, HOYA Corp.'s price-to-earnings ratio is 36.75x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.62x versus 12.90x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPYHOYA Corp.8.62x 36.75x $1.6B $372.7M PPTDFPeptiDream Inc.12.90x 13.79x $29.3M -$7.4M
-
Which has Higher Returns HOCPY or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -24.76%. HOYA Corp.'s return on equity of 21.03% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital HOCPYHOYA Corp.79.54% $1.10 $7.1B SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About HOCPY or SOLTF?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe HOYA Corp. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings HOCPYHOYA Corp.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is HOCPY or SOLTF More Risky?
HOYA Corp. has a beta of 1.019, which suggesting that the stock is 1.938% more volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock HOCPY or SOLTF?
HOYA Corp. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 21.95% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPY or SOLTF?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. HOYA Corp.'s net income of $372.7M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, HOYA Corp.'s price-to-earnings ratio is 36.75x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.62x versus 2.56x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPYHOYA Corp.8.62x 36.75x $1.6B $372.7M SOLTFNxera Pharma Co., Ltd.2.56x -- $45.8M -$11.3M
-
Which has Higher Returns HOCPY or STMM?
Stemcell Holdings, Inc. has a net margin of 23.44% compared to HOYA Corp.'s net margin of --. HOYA Corp.'s return on equity of 21.03% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital HOCPYHOYA Corp.79.54% $1.10 $7.1B STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About HOCPY or STMM?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that HOYA Corp. has higher upside potential than Stemcell Holdings, Inc., analysts believe HOYA Corp. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings HOCPYHOYA Corp.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is HOCPY or STMM More Risky?
HOYA Corp. has a beta of 1.019, which suggesting that the stock is 1.938% more volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock HOCPY or STMM?
HOYA Corp. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HOYA Corp. pays 21.95% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios HOCPY or STMM?
HOYA Corp. quarterly revenues are $1.6B, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. HOYA Corp.'s net income of $372.7M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, HOYA Corp.'s price-to-earnings ratio is 36.75x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.62x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPYHOYA Corp.8.62x 36.75x $1.6B $372.7M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns HOCPY or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 23.44% compared to HOYA Corp.'s net margin of -1.05%. HOYA Corp.'s return on equity of 21.03% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital HOCPYHOYA Corp.79.54% $1.10 $7.1B TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About HOCPY or TAK?
HOYA Corp. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 13.63%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than HOYA Corp., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than HOYA Corp..
Company Buy Ratings Hold Ratings Sell Ratings HOCPYHOYA Corp.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is HOCPY or TAK More Risky?
HOYA Corp. has a beta of 1.019, which suggesting that the stock is 1.938% more volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock HOCPY or TAK?
HOYA Corp. has a quarterly dividend of $0.80 per share corresponding to a yield of 0%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.2% to investors and pays a quarterly dividend of $0.32 per share. HOYA Corp. pays 21.95% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. HOYA Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios HOCPY or TAK?
HOYA Corp. quarterly revenues are $1.6B, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. HOYA Corp.'s net income of $372.7M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, HOYA Corp.'s price-to-earnings ratio is 36.75x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 200.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HOYA Corp. is 8.62x versus 1.70x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income HOCPYHOYA Corp.8.62x 36.75x $1.6B $372.7M TAKTakeda Pharmaceutical Co., Ltd.1.70x 200.00x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
